Cabozantinib in Advanced Salivary Gland Cancer Patients

Inclusion Criteria:

Disease specific

* locally advanced, recurrent, and/or metastatic SGC (excluding sarcomas and mesenchymal tumors)
* c-MET positive disease
* Measurable disease per RECIST version 1.1 Cohort-specific criteria
* SDC cohort: direct inclusion (no objective tumor growth prior to inclusion needed)
* ACC cohort: inclusion after objective growth in the last three months or complaints due to the disease
* Other SGC's: inclusion after objective growth in the last three months or complaints due to the disease General conditions
* Age ≥18 years
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Normal number of neutrophils and thrombocytes
* Liver function: ALT and AST \< 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN (except for Gilbert's syndrome), serum albumin ≥28 g/L
* Renal function: creatinine \< 1.5 x ULN or calculated creatinine clearance ≥ 40 ml/min, Urine protein/creatinine ratio ≤113.1 mg/mmol (≤1 mg/mg) or 24-hour urine protein \<1 g
* Hemoglobin A1c (HbA1c) ≤ 8% or a fasting serum glucose ≤ 9 mmol/l

Exclusion Criteria:

General conditions

* A known allergy for cabozantinib or its components
* Long QT-syndrome
* Pregnancy or lactation
* Patients (M/F) with reproductive potential not implementing adequate contraceptives measures
* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before inclusion
* Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before inclusion and from minor surgery at least 10 days before inclusion
* Uncontrolled illness including, but not limited to cardiovascular disorders including symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias, uncontrolled hypertension defined as sustained systolic BP \> 150 mm Hg, or diastolic BP \> 100 mm Hg, stroke (including TIA), myocardial infarction, or other ischemic event within 6 months before inclusion, serious active infections Concomitant treatments
* Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation.
* Concurrent treatment with any other anti-cancer therapy.
* Concomitant anticoagulation. Low dose aspirin for cardioprotection and low dose LMWH are permitted.
* Radiation therapy within the last 4 weeks before inclusion